| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
STAFFORDSHIRE, U.K.—Increasingly, scientists are using bacteria to produce a variety of products as therapeutics as well as for other applications. Unfortunately, endogenous proteins and metabolic products within the microbes can contaminate and seriously compromise the desired product. With an eye to eliminating the genes that produce these contaminants, scientists at Cobra Biomanufacturing developed a method that offers higher efficiencies than random recombination and does not rely on exogenous recombinases or transposases. They presented their work in Applied and Environmental Microbiology (2006, 72, 2520-2525).
 
The researchers relied on Xer recombinases, enzymes that naturally occur in most bacterial strains, to remove ("Xer"-cise) target genes in E. coli and B. subtilis strains, and used PCR to confirm their results. With E. coli, they deleted a gene responsible for adding an immunogenic myristoyl group to lipid A and thereby reduced the endotoxicity of the microbe for plasmid DNA production. Similarly, in B. subtilis, they were able to delete the genes responsible for proteases that degrade secreted recombinant proteins.
 
The researchers expect that their technique will become more widely applicable as scientists discover more microbes that carry Xer-sensitive recombination sequences and foresee the possible application of this technology in selective gene removal in eukaryotic organisms.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Blue sinusoidal pulse lines are shown in light blue against a dark blue background, representing a heartbeat signal.

Getting to the heart of drug safety testing

High throughput optical scanning enhances cardiac ion channel analysis for safer drug development.
A blue and orange double-helix representing DNA is undergoing transcription with a large orange shape representing RNA polymerase against a blue background

Harnessing CRISPR-Cas9: Knocking out genes in myeloid cells

Explore the applications of CRISPR-Cas9 technology in therapeutic development for Alzheimer’s disease.
A blue x-ray style image of a human body is shown with the liver illuminated in orange against a dark blue background.

Harnessing liver-on-a-chip models for drug safety

Discover how researchers leverage microphysiological systems in toxicology studies.  
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue